USFDA warning letter for Monroe plant
Monroe facility received a warning letter, potentially delaying injectable product approvals and US growth acceleration.
high · management_commentary
Glenmark Pharmaceuticals Limited — Q1 FY24
Glenmark delivered a strong Q1 FY24 with consolidated revenue of INR 24,106 million, up 22.5% YoY, driven by robust performance in Europe (+73.7%) and ROW (+30.4%).
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
India acute segment slowdown
Slowdown in acute segments like respiratory and anti-infectives may pressure India growth, which is guided to single digits.
medium · management_commentaryDebt and interest cost increase
Net debt at INR 2,947 crore and interest costs doubled YoY due to higher LIBOR, impacting profitability.
medium · analyst_questionGlenmark Life Sciences stake sale uncertainty
Mandatory 7-8% stake sale in GLS by August 2024 may not significantly reduce debt as expected by some analysts.
low · analyst_question